THE KPM GROUP DC LLC

Lobbying for MAHZI THERAPEUTICS · Focused on treating under‐served rare genetic neurodevelopmental disorders

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $20,000.00 income · posted Apr 20, 2026

Lobbying activity 3

Medical/Disease Research/Clinical Labs

Priority review voucher (PRV) re-authorization, ICD-10 codes

Health Issues

Priority review voucher (PRV) re-authorization, ICD-10 codes

Science/Technology

Priority review voucher (PRV) re-authorization, ICD-10 codes

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.